Urine miRNAs: Potential biomarkers for monitoring progression of early stages of diabetic nephropathy

Medical Hypotheses

Volumn 81, Issue 2, 2013, Pages 274-278

  Yang, Yeyi ^a   Xiao, Li ^a   Li, Jun ^a   Kanwar, Yashpal S ^b   Liu, Fuyou ^a   Sun, Lin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 144; MICRORNA 192; MICRORNA 21; MICRORNA 216; MICRORNA 217; MICRORNA 375; MICRORNA 377; PLASMA PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ANATOMICAL VARIATION; ARTICLE; BREAST TUMOR; CHRONIC KIDNEY DISEASE; COLON TUMOR; COLORECTAL CANCER; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; EARLY DIAGNOSIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY; KIDNEY DISEASE; LIVER TOXICITY; LUNG TUMOR; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PROSTATE TUMOR; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SOLID TUMOR; STOMACH TUMOR; UPREGULATION; URINARY EXCRETION;

BIOLOGICAL MARKERS; DIABETIC NEPHROPATHIES; HUMANS; MICRORNAS;

EID: 84880044154     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.04.031     Document Type: Article

References (61)

1. Mason R.M., Wahab N.A. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 2003, 14:1358-1373.
2. Satchell S.C., Tooke J.E. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?. Diabetologia 2008, 51:714-725.
3. Navarro-Gonzalez J.F., Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008, 19:433-442.
4. Zhu Y., Usui H.K., Sharma K. Regulation of transforming growth factor beta in diabetic nephropathy: implications for treatment. Semin Nephrol 2007, 27:153-160.
5. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870-878.
6. Jin J., Ku Y.H., Kim Y., Kim K., Lee J.Y., Cho Y.M., et al. Differential proteome profiling using iTRAQ in microalbuminuric and normoalbuminuric type 2 diabetic patients. Exp Diabetes Res 2012, 168602.
7. Liu R., Li G., Cui X.F., Zhang D.L., Yang Q.H., Mu X.Y., et al. Methodological evaluation and comparison of five urinary albumin measurements. J Clin Lab Anal 2011, 25:324-329.
8. Clavant Steven P., Sastra Steve A., Osicka Tanya M., Comper Wayne D. The analysis and characterisation of immuno-unreactive urinary albumin in healthy volunteers. Clin Biochem 2006, 39:143-151.
9. Thongboonkerd V. Study of diabetic nephropathy in the proteomic era. Contrib Nephrol 2011, 170:172-183.
10. Kuokkanen S., Chen B., Ojalvo L., Benard L., Santoro N., Pollard J.W. Genomic profiling of microRNAs and messenger RNAs reveals hormonal regulation in microRNA expression in human endometrium. Biol Reprod 2010, 82:791-801.
11. Divakaran V., Mann D.L. The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res 2008, 103:1072-1083.
12. Youssef Y.M., White N.M., Grigull J., Krizova A., Samy C., Mejia-Guerrero S., et al. Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol 2011, 59:721-730.
13. Chen Y.Q., Wang X.X., Yao X.M., Zhang D.L., Yang X.F., Tian S.F., et al. Abated microRNA-195 expression protected mesangial cells from apoptosis in early diabetic renal injury in mice. J Nephrol 2012, 25:566-576.
14. Feng Y., Yu X. Cardinal roles of miRNA in cardiac development and disease. Sci Chin Life Sci 2011, 54:1113-1120.
15. Roggli E., Gattesco S., Caille D., Briet C., Boitard C., Meda P. Changes in microRNA expression contribute to pancreatic β-cell dysfunction in prediabetic NOD mice. Diabetes 2012, 61:1742-1751.
16. Chen Xi, Ba Yi, Ma Lijia, Cai Xing, Yin Yuan, Wang Kehui Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006.
17. Kurashige J., Kamohara H., Watanabe M., Tanaka Y., Kinoshita K., Saito S., et al. Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. J Surg Oncol 2012, 21. 10.1002/jso.23064.
18. Huang Y., Dai Y., Zhang J., Wang C., Li D., Cheng J., et al. Circulating microRNAs as potential biomarkers for smoking-related interstitial fibrosis. Biomarkers 2012.
19. Gantier M.P., McCoy C.E., Rusinova I., Saulep D., Wang D., Xu D., et al. Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. Nucleic Acids Res 2011, 39:5692-5703.
20. Cortez M.A., Bueso-Ramos C., Ferdin J., Lopez-Berestein G., Sood A.K., Calin G.A. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011, 8:467-477.
21. Wang K., Zhang S., Weber J., Baxter D., Galas D.J. Export of microRNAs and microRNA-protective protein by mammalian cells. Nucleic Acids Res 2010, 38:7248-7259.
22. Hanke M., Hoefig K., Merz H., Feller A.C., Kausch I., Jocham D., et al. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol Semin Original Invest 2010, 28:655-661.
23. Melkonyan H.S., Feaver W.J., Meyer E., Scheinker V., Shekhtman E.M., Xin Z., et al. Transrenal nucleic acids: from proof of principle to clinical tests. Ann N Y Acad Sci 2008, 1137:73-81.
24. Yamada Y., Enokida H., Kojima S., Kawakami K., Chiyomaru T., Tatarano S., et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci 2011, 102:522-529.
25. Ciesla M., Skrzypek K., Kozakowska M., Loboda A., Jozkowicz A., Dulak J. MicroRNAs as biomarkers of disease onset. Anal Bioanal Chem 2011, 401:2051-2061.
26. Argyropoulos C., Wang K., McClarty S., Huang D., Bernardo J., Ellis D., et al. Urinary microRNA profiling in the nephropathy of type 1 diabetes. PLoS One 2013, 8:e54662.
27. Hou J., Shan Q., Wang T., Gomes A.S., Yan Q., et al. Transgenic RNAi depletion of claudin-16 and the renal handling of magnesium. J Biol Chem 2007, 282:17114-17122.
28. Wang G., Kwan B.C.-H., Lai F.M.-M., Chow K.-M., Kam-Tao Li P., et al. Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Dis Markers 2010, 28:79-86.
29. Zampetaki A., Kiechl S., Drozdov I., Willeit P., Mayr U., Prokopi M., et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010, 107:810.
30. Zhao H.L., Guan J., Lee H.M., Sui Y., He L., Siu J.J., et al. Up-regulated pancreatic tissue microRNA-375 associates with human type 2 diabetes through beta-cell deficit and islet amyloid deposition. Pancreas 2010, 39:843-846.
31. Zhang Lin, Volinia Stefano, Bonome Tomas, Adrian Calin George, Greshock Joel, Yang Nuo, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. PNAS 2008, 105:7004-7009.
32. Melkamu T., Zhang X.X., Tan J.K., Zeng Y., Kassie F. Alteration of microRNA expression in vinyl carbamate-induced mouse lung tumors and modulation by the chemopreventive agent indole-3-carbinol. Carcinogenesis 2010, 31:252-258.
33. Chow H.Y., Jubb A.M., Koch J.N., Jaffer Z.M., Stepanova D., Campbell D.A., et al. P21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. Cancer Res 2012, 72:5966-5975.
34. Temneanu R.O., Motoc A., Zugun F.E., Folescu R., Lupuşoru C.E., Zamfir C.L. The relevance of circadian rhythms disruption on pulmonary SOD expression in rat. Rom J Morphol Embryol 2012, 53:789-793.
35. Wang K., Zhang S., Marzolf B., Troisch P., Brightman A., Hu Z., et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 2009, 8(8):4402-4407.
36. Karaayvaz M., Pal T., Song B., Zhang C., Georgakopoulos P., Mehmood S., et al. Prognostic significance of miR-215 in colon cancer. Clin Colorectal Cancer 2011, 10:340-347.
37. Wang G., Kwan B.C.H., Lai F.M.M., Chow K.M., Li P.K.T., Szeto C.C. Expression of microRNAs in the urinary sediment of patients with IgA nephropathy. Dis Markers 2010, 28:79-86.
38. Wang G., Kwan B.C., Lai F.M., Choi P.C., Chow K.M., Li P.K., Szeto C.C. Intrarenal expression of miRNAs in patients with hypertensive nephrosclerosis. Am J Hypertens 2010, 23:78-84.
39. Wang B., Herman-Edelstein M., Koh P., Burns W., Jandeleit-Dahm K., Watson A., et al. E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. Diabetes 2010, 59:1794-1802.
40. Krupa A., Jenkins R., Luo D.D., Lewis A., Phillips A., Fraser D. Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol 2010, 21:438-447.
41. Putta S., Lanting L., Sun G., Lawson G., Kato M., Natarajan R. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol 2012, 23:458-469.
42. Krupa A., Jenkins R., Luo D.D., Lewis A., Phillips A., Fraser D. Loss of microRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol 2010, 21:438-447.
43. Szafranska A.E., Davison T.S., John J., Cannon T., Sipos B., Maghnouj A., et al. MicroRNA expression alterations are linked to tumorigenesis & non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007, 26:4442-4452.
44. Li J.Y., Yong T.Y., Michael M.Z., Gleadle J.M. Review: the role of microRNAs in kidney disease. Nephrology (Carlton) 2010, 15:599-608.
45. Kato M., Putta S., Wang M., Yuan H., Lanting L., Nair I., et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 2009, 11:881-889.
46. Liu Y., Wang X., Jiang J., Cao Z., Yang B., Cheng X., et al. Modulation of T cell cytokine production by miR-144* with elevated expression in patients with pulmonary tuberculosis. Mol Immunol 2011, 48:1084-1090.
47. Huang F., Huang X.Y., Yan D.S., Zhou X., Yang D.Y., et al. MicroRNA-144 over-expression induced myocytes apoptosis. Zhonghua Xin Xue Guan Bing Za Zhi 2011, 39:353-357.
48. Sureban S.M., May R., Lightfoot S.A., Hoskins A.B., Lerner M., Brackett D.J., et al. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res 2011, 71:2328-2338.
49. Kalimutho M., Del Vecchio Blanco G., Di Cecilia S., Sileri P., Cretella M., Pallone F., et al. Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J Gastroenterol 2011, 46:1391-1402.
50. Karolina D.S., Armugam A., Tavintharan S., Wong M.T., Lim S.C., Sum C.F., et al. MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One 2011, 6:e22839.
51. Chow T.F.F., Youssef Y.M., Lianidou E., Romaschin A.D., Honey R.J., Stewart R., et al. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem 2010, 43:150-158.
52. Zhang Z., Peng H., Chen J., Chen X., Han F., Xu X., et al. MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett 2009, 583:2009-2014.
53. Zhao H., Yang J., Fan T., Li S., Ren X. RhoE functions as a tumor suppressor in esophageal squamous cell carcinoma and modulates the PTEN/PI3K/Akt signaling pathway. Tumour Biol 2012, 33:1363-1374.
54. O'Connor J.C., Sherry C.L., Guest C.B., Freund G.G. Type 2 diabetes impairs insulin receptor substrate-2-mediated phosphatidylinositol 3-kinase activity in primary macrophages to induce a state of cytokine resistance to IL-4 in association with overexpression of suppressor of cytokine signaling-3. J Immunol 2007, 178:6886-6893.
55. Mahimainathan L., Das F., Venkatesan B., Choudhury G.G. Mesangial cell hypertrophy by high glucose is mediated by downregulation of the tumor suppressor PTEN. Diabetes 2006, 55:2115-2125.
56. Dai X., Chiang Y., Wang Z., Song Y., Lu C., Gao P., et al. Expression levels of microRNA-375 in colorectal carcinoma. Mol Med Report 2012, 5:1299-1304.
57. Kong K.L., Kwong D.L., Chan T.H., Law S.Y., Chen L., Li Y., et al. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 2012, 61:33-42.
58. Kaucsar T., Racz Z., Hamar P. Post-transcriptional gene-expression regulation by micro RNA (miRNA) network in renal disease. Adv Drug Deliv Rev 2010, 62:1390-1401.
59. El Ouaamari A., Baroukh N., Martens G.A., Lebrun P., Pipeleers D., van Obberghen E., et al. MiR-375 targets 3'-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes 2008, 57:2708-2717.
60. Fan R., Kim N.G., Gumbiner B.M. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. Proc Natl Acad Sci USA 2013, 110:2569-2574.
61. Neal C.S., Michael M.Z., Pimlott L.K., Yong T.Y., Li J.Y., Gleadle J.M. Circulating microRNA expression is reduced in chronic kidney disease. Nephrol Dial Transplant 2011, 26:3794-3802.